Actively Recruiting
Observational Study of Surgical Management Using Efanesoctocog Alfa Altuvoct in Patients with Hemophilia A
Led by Hospices Civils de Lyon · Updated on 2026-07-23
160
Participants Needed
1
Research Sites
135 weeks
Total Duration
AI-Summary
What This Trial Is About
Hemophilia A is a genetic bleeding disorder caused by a lack or low levels of clotting factor VIII. This observational study focuses on patients with Hemophilia A undergoing surgery and treated with Efanesoctocog alfa Altuvoct, a new type of factor VIII therapy with a very long half-life. The study aims to collect real-world data on surgical management and compare outcomes to those from another factor VIII treatment, efmoroctocog alfa, used in a similar study in France. Participants will be grouped based on their treatment some will receive Efanesoctocog alfa alone, while others will have combined therapy with Efanesoctocog alfa and emicizumab. Researchers will gather clinical data including the surgical setting inpatient or outpatient, the number of factor VIII infusions during surgery, how long patients stay in the hospital, when they return to their usual prophylaxis, and overall factor VIII use. This multicenter study helps address variations in treatment practices and supports better harmonization of care across centers. During the study, participants will be monitored from the preoperative dose until up to 14 days after surgery to track the use of Altuvoct for hemostatic control. Data collected will help understand the role of this ultra-extended half-life factor VIII in perioperative care. The study duration extends until October 2028, and findings will provide insights into optimizing surgical treatment for patients with Hemophilia A.
CONDITIONS
Brief Title
Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here